文献速递淋巴瘤

可测量残留病并非新型慢性淋巴细胞白血病治疗试验中无进展生存的普遍可靠替代终点

Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies.
PubMed 文献 · Leukemia · 2026-04-30

该研究检索多个数据库至2025年2月8日,纳入43项试验共9628例受试者,评估可测量残留病(MRD)预测无进展生存(PFS)的准确性。个体水平可检测MRD者进展或死亡风险显著更高(HR=3.67),但试验水平MRD与PFS相关性弱(R=-0.33),尤其在BTK抑制剂和维奈克拉方案中。MRD作为PFS替代终点的准确性取决于治疗方式、药物类型和采样来源,需谨慎解读。

要点

  • 个体水平可检测MRD与更高进展或死亡风险相关(HR=3.67)。
  • 试验水平MRD与PFS相关性弱,尤其在BTK抑制剂和维奈克拉方案中。
  • MRD替代PFS的准确性受治疗方式、药物类型和采样来源影响。

核心结论

  • MRD检测结果作为PFS替代终点的准确性具有情境依赖性,受治疗方式、药物类型和采样来源影响,用于临床或监管决策时应谨慎解读。

研究设计与样本

  • 检索PubMed、Web of Science、Embase和Cochrane Library至2025年2月8日,纳入43项试验共9628例受试者,评估MRD预测PFS的准确性。

主要发现

  • 个体水平可检测MRD者进展或死亡风险显著高于不可检测MRD者(HR=3.67;95% CrI 3.34, 4.03;P < 0.01)。
  • 试验水平MRD与PFS相关性弱(Spearman R=-0.33;R²=0.06),BTK抑制剂治疗(R=-0.05,R²=0.03)和维奈克拉方案(R=-0.28,R²=0.02)中更弱。
  • 化学免疫治疗和/或单克隆抗体治疗中相关性较强,骨髓MRD预测PFS较血液更准确(R=-0.94;R²=0.86)。
  • 固定疗程治疗的敏感性分析中治疗效应相关性接近预设效度阈值(R=-0.80 [-0.93, -0.53];R²=0.43,P < 0.01)。

临床怎么用

  • 在新型CLL治疗试验中,不应将MRD普遍视为PFS的可靠替代终点,需结合治疗类型和采样来源谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Several recent trials of new chronic lymphocytic leukemia (CLL) therapies used results of measurable residual disease (MRD)-testing as a primary endpoint assuming it is an accurate surrogate for progression-free survival (PFS) which is, itself, a surrogate endpoint for survival. But whether MRD-testing results accurately correlates with PFS following Bruton tyrosine kinase-inhibitor (BTK-i) therapy with or without venetoclax or for fixed duration therapy regimens is controversial. We searched PubMed, Web of Science, Embase, and Cochrane Library up to February 8, 2025, identifying 43 trials involving 9628 subjects to assess MRD's accuracy in predicting PFS. At the individual-level subjects with detectable MRD (dMRD) had a significantly higher risk of progression or death than those with undetectable MRD (uMRD; Hazard Ratio [HR] = 3.67; 95% Credibility Interval [CrI] 3.34, 4.03; P < 0.01). In contrast, MRD-testing results and PFS were weak at the trial-level (Spearman rho [R] = -0.33; Determination Coefficients [R² ] = 0.06), especially for BTKi- therapy (R = -0.05, R² = 0.03) and venetoclax-based therapies (R = -0.28, R² = 0.02). Correlations were stronger for therapies involving drugs such as chemoimmunotherapy and/or monoclonal antibodies, where MRD tests of bone marrow (R = -0.94; R2 = 0.86) were more accurately predicted PFS than blood. In sensitivity analyses stratified by treatment approach we found a correlation of treatment-effect in fixed-duration therapy approaching the pre-specified validity threshold (R = -0.80 [-0.93, -0.53]; R² = 0.43, P < 0.01). Our data indicate the accuracy of MRD-testing results to surrogate PFS is context-dependent, influenced by treatment approach, therapy type, and the sampling source, and should be interpreted cautiously when informing clinical or regulatory decisions.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Wang Y, Li C, Gale RP, et al. Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies. Leukemia. 2026. PMID: 42062556. doi:10.1038/s41375-026-02970-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。